Ferring's Propess approved for cervical ripening in Japan

23 January 2020

Propess (dinoprostone) has been approved by the Minister of Health, Labour and Welfare in Japan for initiation of cervical ripening in patients at term.

The Ferring Pharmaceuticals drug is the first pharmacological therapy to be approved for cervical ripening in the Asian country for more than 20 years.

Propess, a treatment developed in Scotland, UK, is now marketed in more than 60 countries. It was approved following close collaboration with a patient advocacy group in Japan and offers women requiring an induction greater choice of alternatives to mechanical methods of cervical ripening.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK